From the article:

The three founders of Encora who are still with the company are Carballo, Allison Davanzo ’18, and Kyle Pina ’18. They were each seniors in 2017 when they enrolled in 2.009, MIT’s popular product-design class.

The semester began with a brainstorming session in which groups of about 17 students were asked to come up with dozens of potential product ideas. Carballo proposed a wearable device that used mechanical vibration to send signals to the brain to reduce tremors. The initial idea was to help patients with Parkinson’s disease.

“It was one of hundreds of throwaway ideas,” Carballo recalls. “The initial concept was inspired by classes I had taken in robotics around neural control of movement. I had a preliminary understanding of how an electromechanical device might interact with the body’s control systems and feedback loops that control movement to relieve pathological control of movement.”

The team eventually whittled their long list of ideas down to a few. Carballo’s idea was finally selected by a vote of 16-1 — with Carballo the only dissenting vote.

“I tried to explain to the team that this was so far-fetched that there was no way, in one semester, we would be able to make anything,” Carballo recalls. “Thankfully, I got outvoted.”

[...]

One current approach to target those signals is surgery that involves drilling holes in the skull to insert electrodes that drive new electrical patterns in the brain. Encora’s watch-like product targets the same brain regions with mechanical vibrations at the wrist.

“We’re applying mechanical stimulus, basically vibration, to stretch receptors in the wrist, which tell your body where it is in space,” Carballo explains. “The stimulation causes the receptors to activate and send a patterned signal to peripheral nerves of the wrist, that then carry the signal to the peripheral nervous system and into the central nervous system, to the same regions of the brain targeted by surgery.”

In 2024, Encora ran a randomized control trial with 47 patients living with essential tremor. Last year, the team ran a 59-person trial where patients used the devices at home. In both trials, more than 70 percent of patients experienced meaningful improvement.

The results were promising enough to gain what’s known as 510(k) clearance from the FDA for use as a medical device, in February of this year.

[...]

Today, Encora is focused on building a national sales force and working to secure coverage from insurers. As the company ramps up production, the product will finally become available for patients who qualify.